ANECOVA is a life sciences company focused on the development and commercialization of novel technologies in the field of medically assisted procreation with the aim of improving results and the overall quality of care through the use of more physiologic and natural processes.
 
The first ANECOVA device restores the fertilization and early embryonic development phases back into the physiologic environment of the maternal uterus instead of the laboratory incubator. This permits the development of the embryos in close communication and exchange with maternal factors from the very start of life. Moreover, the embryos mature in a milieu protected from the uncontrollable variables and potentially deleterious external factors that are inevitable in the traditional in vitro culture.
 
A positive influence is expected on both the number and the individual quality of the embryos thus produced which should translate into better overall results of assisted reproduction.
 
The preliminary results already obtained have been very encouraging. ANECOVA is currently undertaking clinical evaluation programs in close collaboration with international experts in the field, pursuing its quest for the highest quality of medical solutions to bring to patients worldwide.